Venlafaxine Extended-Release Tablets Recalled for Missing Tablet Identification
Appco Pharma LLC is recalling Venlafaxine Extended-Release Tablets, 150mg, due to missing tablet identification imprints. The defect affects 1,380 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. The hazard is a manufacturing specification failure—missing tablet identification—classified as a labeling defect rather than a safety hazard with reported harm.
Plain-English summary
Appco Pharma LLC is recalling Venlafaxine Extended-Release Tablets, 150mg (NDC 43598-943-90), Lot #2402101UR, expiration 02/28/2027, due to a manufacturing specification failure. The tablets lack the identification number imprint on either side of the tablet.
The affected product consists of 1,380 bottles distributed nationwide throughout the United States.
The recalled product
- Product
- VENLAFAXINE (VENLAFAXINE)
- Brand
- VENLAFAXINE
- Manufacturer
- Appco Pharma LLC
- Category
- Drug — Antidepressant
- Hazard
- missing-imprint
- labeling-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 2402101UR
- Exp 02/28/2027
UPCs (4)
- 0343598943909
- 0343598944906
- 0343598944302
- 0343598943305
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VENLAFAXINE
- HighPrescription Drug Recall: Venlafaxine Tablets Contaminated With Foreign Metal Material
FDA (Drugs) · 2025-04-16
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27